Viral Evasion of the Integrated Stress Response Through Antagonistic eIF2-P Mimicry

Michael Schoof^{1,2,#}, Lan Wang^{1,2,#}, J Zachery Cogan^{1,2}, Rosalie Lawrence^{1,2}, Morgane Boone^{1,2}, Jennifer Deborah Wuerth³, Adam Frost^{2,4}, Peter Walter^{1,2,*}

Affiliations

¹Howard Hughes Medical Institute, University of California at San Francisco, San Francisco, CA, USA.

²Department of Biochemistry and Biophysics, University of California at San Francisco, San Francisco, CA, USA.

³Institute of Innate Immunity, Medical Faculty, University of Bonn, Bonn, Germany

⁴Chan Zuckerberg Biohub, San Francisco, CA, USA.

These authors contributed equally

* To whom correspondence should be addressed; Email: Peter@walterlab.ucsf.edu

Abstract

Viral infection triggers activation of the integrated stress response (ISR). In response to viral double-stranded RNA (dsRNA), RNA-activated protein kinase (PKR) phosphorylates the translation initiation factor eIF2, converting it from a translation initiator into a potent translation inhibitor and this restricts the synthesis of viral proteins. Phosphorylated eIF2 (eIF2-P) inhibits translation by binding to eIF2's dedicated, heterodecameric nucleotide exchange factor eIF2B and conformationally inactivating it. We show that the NSs protein of Sandfly Fever Sicilian virus (SFSV) allows the virus to evade the ISR. Mechanistically, NSs tightly binds to eIF2B ($K_D = 43$ nM), blocks eIF2-P binding, and rescues eIF2B GEF activity. Cryo-EM structures demonstrate that SFSV NSs and eIF2-P directly compete, with the primary NSs contacts to eIF2B α mediated by five 'aromatic fingers'. NSs binding preserves eIF2B activity by maintaining eIF2B's conformation in its active A-State.

Introduction

The Integrated Stress Response (ISR) is a conserved eukaryotic stress response network that, upon activation by a diverse set of stressors, profoundly reprograms translation. It is coordinated by at least four stress-responsive kinases: PERK (responsive to protein misfolding in the endoplasmic reticulum), PKR (responsive to viral infection), HRI (responsive to heme deficiency and oxidative and mitochondrial stresses), and GCN2 (responsive to nutrient deprivation) [1-4]. All four known ISR kinases converge on the phosphorylation of a single serine (S51) of the α subunit of the general translation initiation factor eIF2. Under non-stress conditions, eIF2 forms a ternary complex (TC) with methionyl initiator tRNA (Met-tRNAⁱ) and GTP. This complex performs the critical task of delivering the first amino acid to ribosomes at AUG initiation codons. Upon S51 phosphorylation, eIF2 is converted from a substrate to an inhibitor of its dedicated nucleotide exchange factor (GEF) eIF2B. GEF inhibition results from binding of eIF2-P in a new, inhibitory binding orientation on eIF2B, where it elicits allosteric changes to antagonize eIF2 binding and additionally compromise eIF2B's intrinsic enzymatic activity [5, 6].

eIF2B is a two-fold symmetric heterodecamer composed of 2 copies each of α , β , δ , γ , and ϵ subunits [7-10]. eIF2B can exist in a range of stable subcomplexes (eIF2B $\beta\delta\gamma\epsilon$ tetramers and eIF2B α_2 dimers) if the concentrations of its constituent subunits are altered [5, 8, 9, 11]. While earlier models suggested eIF2B assembly to be rate-limiting and a potential regulatory step, recent work by us and others show that eIF2B in cells primarily exists in its fully assembled decameric, enzymatically active state [5, 6]. Cryo-EM studies of various eIF2B complexes elucidated the mechanisms of nucleotide exchange and ISR inhibition through eIF2-P binding [5, 6, 12-15]. Under non-stress conditions, eIF2 engages eIF2B through multiple interfaces along a path spanning the heterodecamer. In this arrangement, eIF2 α binding to eIF2B critically positions the GTPase domain in eIF2's γ subunit, allowing for efficient catalysis of nucleotide exchange. eIF2B's catalytically active conformation ('A-State') becomes switched to an inactive conformation upon eIF2-P binding (Inhibited or 'I-State'), which displays altered substrate-binding interfaces. I-State eIF2B($\alpha\beta\delta\gamma\epsilon$)₂ exhibits enzymatic activity and substrate engagement akin to the tetrameric eIF2B $\beta\delta\gamma\epsilon$ subcomplex, hence eIF2-P inhibition of eIF2B converts the decamer into conjoined tetramers, which reduces its

GEF activity, lowers the cell's TC concentration, and results in ISR-dependent translational reprogramming.

Viruses hijack the host cell's protein synthesis machinery to produce viral proteins and package new viral particles. Numerous host countermeasures have evolved. In the context of the ISR, double-stranded RNA (dsRNA), a by-product of viral replication, triggers dimerization and autophosphorylation of PKR [3, 16]. In this activated state PKR phosphorylates eIF2, which then binds to and inhibits eIF2B. As such, cells downregulate mRNA translation as a strategy to slow the production of virions. Viruses, in turn, enact strategies of evasion. Indeed, viral evasion strategies acting at each step of ISR activation have been observed. Influenza virus, for example, masks its dsRNA [17, 18]. Rift Valley Fever virus (RVFV) encodes an effector protein that degrades PKR [19]. Hepatitis C virus blocks PKR dimerization [20]. Vaccinia virus encodes a pseudosubstrate as a PKR decoy [21]. Herpes simplex virus can dephosphorylate eIF2-P [22]. And some coronavirus and picornavirus proteins appear to block the eIF2B-eIF2-P interaction [23]. This evolutionary arms race between host and pathogen can provide invaluable tools and insights into the critical mechanisms of the ISR, as well as other cellular stress responses.

Here, we investigated the previously unknown mechanism by which Sandfly Fever Sicilian virus (SFSV) evades the ISR. SFSV and RVFV are both members of the genus *Phlebovirus* (order *Bunyavirales*) which encode an evolutionarily related non-structural protein (NSs) [24-26]. Across the phleboviruses, NSs serves to counteract the antiviral interferon response, but NSs proteins perform other functions as well [27, 28]. Unlike the RVFV NSs which degrades PKR, SFSV NSs does not impact the levels or phosphorylation status of PKR or eIF2 [19, 29]. Instead, it binds to eIF2B, inhibiting the ISR. The mechanistic basis of this inhibition was previously unclear. We here provide cellular, biochemical, and structural insight into this question, showing that the SFSV NSs evades all branches of the ISR by binding to eIF2B and selectively blocking eIF2-P binding, thereby maintaining eIF2B in its active A-State.

Results

The SFSV NSs is a pan ISR inhibitor

To dissect the role of the SFSV NSs (henceforth referred to as NSs) in ISR modulation, we engineered cells stably expressing either an empty vector, a functional NSs (NSs::FLAG), or a non-functional NSs (FLAG::NSs) (Extended Data Fig. 1). As previously reported, the NSs with a C-terminal FLAG tag (NSs::FLAG) should retain its PKR-evading properties while tagging at the N-terminus (FLAG::NSs) blocks this functionality [29]. These constructs were genomically integrated into our previously generated ISR reporter system, in which both changes in ATF4 translation and general translation can be monitored [5]. Both NSs::FLAG and FLAG::NSs were stably expressed in these cells without impacting the levels of key ISR components (eIF2B, eIF2, PKR, PERK) (Fig. 1a). The apparent differences in band intensity between NSs::FLAG and FLAG::NSs may reflect differences in protein stability or, perhaps more likely, differences in antibody affinity for the FLAG epitope at the respective C- and N-terminal tagging locations.

To ask whether NSs is a pan-ISR inhibitor capable of dampening ISR activation irrespective of any particular ISR activating kinase, we chemically activated PERK, HRI, and GCN2 with thapsigargin, oligomycin, and glutamine deprivation / synthetase inhibition through L-methionine sulfoximine, respectively. NSs::FLAG expression dampened the increases in ATF4 translation brought about by activation of any of the kinases (Fig. 1b-d). NSs::FLAG also maintained general translation levels in the thapsigargin and oligomycin treated cells (Fig. 1b,c). Notably, in the context of GCN2 activation, general translation comparably decreased at the highest levels of stress regardless of NSs status (Fig. 1d). This observation likely reflects the additional stress responses that react to reduced amino acid levels, as well as the fact that while the ISR controls translation initiation, ribosome-engaged mRNAs still need sufficient levels of amino acids to be successfully translated. On the whole, these data therefore show that the NSs is a pan-ISR inhibitor akin to the small molecule ISRIB, which binds to eIF2B and counteracts the ISR by allosterically blocking eIF2-P binding and promoting eIF2B complex assembly when eIF2B's decameric state is compromised [5, 6, 30].

NSs binds decameric eIF2B exclusively

To explain the mechanism by which NSs inhibits the ISR, we purified NSs expressed in mammalian cells (Fig. 2a,b). We next validated that NSs binds to eIF2B *in vitro* by immobilizing distinct eIF2B complexes on agarose beads and incubating them with an excess of NSs (Fig. 2c). As expected, NSs binds to the fully assembled eIF2B($\alpha\beta\delta\gamma\epsilon$)₂ decamers (Lane 4). Notably, it did not bind to eIF2B $\beta\delta\gamma\epsilon$ tetramers (Lane 5) or to eIF2B α_2 dimers (Lane 6). The NSs interaction with eIF2B thus either spans multiple interfaces that are only completed in the fully assembled complex or interacts with a region of eIF2B that undergoes a conformational change when in the fully assembled state.

To quantitatively assess NSs binding to eIF2B, we employed surface plasmon resonance (SPR) experiments to determine the affinity of NSs for the various eIF2B complexes (Fig. 2d-f). The NSs interaction with decameric eIF2B could be modeled using one-phase association and dissociation kinetics. NSs binds to decameric eIF2B with a K_D of 43 nM ($k_a = 2.0 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$, $k_d = 8.7 \times 10^{-3} \text{ s}^{-1}$) (Fig. 2d). In this orthogonal approach, we again observed no detectable binding of NSs to eIF2B $\beta\delta\gamma\epsilon$ tetramers or eIF2B α_2 dimers (Fig. 2e,f).

NSs rescues eIF2B activity by blocking eIF2-P binding

We next sought to explain the mechanism of NSs inhibition of the ISR using our established *in vitro* systems for studying eIF2B. As is the case with the small molecule ISRIB, NSs did not impact the intrinsic nucleotide exchange activity of eIF2B as monitored by a fluorescent BODIPY-FL-GDP loading assay (Extended Data Fig. 2). To mimic the conditions during ISR activation, we repeated our nucleotide exchange assay in the presence of the inhibitory eIF2 α -P (Fig. 3a). As expected, eIF2 α -P inhibited eIF2B GEF activity ($t_{1/2} = 13.4 \text{ min}$, s.e.m. = 1.5 min), but increasing concentrations of NSs (25 nM: $t_{1/2} = 9.2 \text{ min}$, s.e.m. = 1.2 min; 100 nM: $t_{1/2} = 6.2 \text{ min}$, s.e.m. = 0.5 min) overcame the inhibitory effects of eIF2 α -P and fully rescued eIF2B GEF activity (uninhibited $t_{1/2} = 6.3 \text{ min}$, s.e.m. = 0.6 min).

As NSs' ability to affect eIF2B activity manifests in the presence of eIF2 α -P, we wondered whether NSs blocks eIF2 α -P binding to eIF2B. To test this notion, we utilized a fluorescent ISRIB analog (FAM-ISRIB) that emits light with a higher degree of polarization when bound to eIF2B, compared to being free in solution (Fig. 3b, black and

red dots on the Y axis, respectively). It has been previously shown that eIF2 α -P binding to eIF2B antagonizes FAM-ISRIB binding by shifting eIF2B into a conformation incapable of binding ISRIB or its analogs (Fig. 3b, blue dot on the Y axis) [5, 6]. A titration of NSs into this reaction recovered FAM-ISRIB polarization ($EC_{50} = 72$ nM, s.e.m. = 9 nM), indicating that NSs engages eIF2B and disrupts eIF2 α -P's inhibitory binding. To directly show this antagonism, we immobilized eIF2B decamers on agarose beads and incubated with combinations of NSs and eIF2 α -P, using a NSs concentration (1 μ M) >10x above the EC_{50} from Fig. 3b (72 nM) to ensure a complete blockade of eIF2 α -P binding (Fig. 3c). While individually, both eIF2 α -P and NSs bound to eIF2B (Fig. 3c, lanes 4 and 5, respectively), in the presence of saturating NSs, eIF2 α -P no longer bound eIF2B (Fig. 3c, lane 6). Together, these results demonstrate that the NSs is a potent inhibitor of eIF2-P binding.

NSs binds to eIF2B at the eIF2 α -P binding site and keeps eIF2B in the active A-State

Having established that the NSs blocks eIF2-P binding to eIF2B, we next assessed whether NSs is an allosteric regulator of eIF2-P binding (as is the case with ISRIB) or, alternatively, whether it directly competes with eIF2-P binding. To answer this question and to rigorously determine NSs' interactions with eIF2B, we turned to cryoEM. To obtain a homogeneous sample suitable for structural studies, we mixed full-length NSs with decameric eIF2B at a 3:1 molar ratio. We then prepared the sample for cryo-EM imaging and determined the structure of the eIF2B-NSs complex.

3D classification with no symmetry assumptions yielded a distinct class of 137,093 particles. Refinement of this class resulted in a map with an average resolution of 2.6 Å (Extended Data Fig. 3). After docking the individual eIF2B subunits into the recorded density, we observed significant extra density next to both eIF2B α subunits, indicating that two copies of NSs are bound to each eIF2B decamer (Extended Data Fig. 3). The local resolution of the NSs ranges from 2.5 Å (regions close to eIF2B) to >4.0 Å (periphery), with most of the side chain densities clearly visible (Extended Data Fig. 3). To build the molecular model for NSs, we split the protein into two domains. The C-terminal domain was built using the crystal structure of the C-terminal domain of the RVFV NSs (PDB ID: 5OOO) as a homology model (43.8% sequence similarity with the C-terminal domain of the SFSV NSs (residues 85-261)) (Extended Data Fig. 4) [31]. The

N-terminal domain of the NSs (residues 1-84) was built *de novo* (Extended Data Table 1). The high resolution map allowed us to build a model for the majority of NSs. The map quality of both NSs molecules are comparable, and their molecular models are nearly identical (root mean square deviation (RMSD) ≈ 0.2 Å). We henceforth focus our analysis on one of them (chain K).

Two copies of NSs bind to one decameric eIF2B in a symmetric manner (Fig. 4a). An overlay of the NSs-bound eIF2B and the eIF2 α -P-bound eIF2B structures (PDB ID: 6O9Z) shows a significant clash between the NSs and eIF2- α P, indicating that, unlike the allosteric regulator ISRIB, NSs binds in direct competition with eIF2 α -P (Fig. 4d-f). Interestingly, whereas eIF2 α -P forms extensive interactions with both the α and the δ subunits of eIF2B, the NSs mainly interacts with the eIF2B α subunit. The expansive interactions between eIF2 α -P and both eIF2B α and eIF2B δ mediate a shift in eIF2B's conformation from eIF2B's enzymatically active A-state to its inhibited I-state [5, 6]. Thus, despite binding to a region known to influence eIF2B's conformation, an overlay of the NSs-bound eIF2B and apo-eIF2B shows that the overall conformation of eIF2B in the two structures are virtually identical (Fig. 4b). By contrast, the eIF2B-NSs and eIF2B-eIF2 α -P overlay shows major conformational differences (Fig. 4c). Together, these structural data, paired with our *in vitro* assays, show that the NSs grants SFSV evasion of the ISR by directly competing off eIF2-P and restoring eIF2B to its enzymatically active A-state.

NSs uses a novel protein fold containing aromatic fingers to bind eIF2B

Next, we sought to interrogate the molecular details of the NSs-eIF2B interaction. As mentioned above, NSs consists of two domains. Its N-terminal domain (amino acids 1-84) consists of six β strands and interacts directly with eIF2B. A search in the DALI protein structure comparison server did not reveal any hits, suggesting a novel protein fold. β strands 1 and 2 and β strands 3 and 4 form two antiparallel β sheets and fold on top of the C-terminal domain (Extended Data Fig. 5b). The C-terminal domain (amino acids 85-261) is largely α -helical and presumably supports the folding of the N-terminal domain, as truncating the C-terminal domain results in the complete loss of NSs activity in terms of ISR evasion (Extended Data Fig. 6). Also, despite the moderate sequence conservation of the C-terminal domain of the SFSV NSs and the RVFV NSs, their structures overlay extensively (RMSD ≈ 1.4 Å, Extended Data Fig. 5).

The surface of the N-terminal domain forms a hand shape that grips the alpha helices of eIF2B α , akin to a koala grabbing a eucalyptus branch (Fig. 5a, Extended Data Fig. 8). In this arrangement, the N-terminal domain extends three loops that contact eIF2B α . The first two loops sit in a groove between helices α 3 and α 4 and the third loop just below helix α 3, effectively sandwiching helix α 3 (Fig. 5b). Together, the three loops extend five aromatic amino acids to contact eIF2B α . We refer to these aromatic amino acids as “aromatic fingers”. On the top side of helix α 3, the side chain of NSs Y5 forms a cation- π interaction with eIF2B α R74 and its backbone carbonyl forms a hydrogen bond with eIF2B α R46 (Fig. 5d). NSs F5 forms a cation- π interaction with eIF2B α R46, and hydrophobic stacking with eIF2B α I42. NSs F33 stacks against the backbone of eIF2B α Y304 and L305, as well as the aliphatic region of eIF2B α R74. On the bottom side of helix α 3, NSs F80 stacks against a hydrophobic groove formed by eIF2B α I7, F33 and A52 (Fig. 5e). NSs Y79 forms a polar interaction with eIF2B α D37, completing the extensive interaction network of the NSs’ aromatic fingers with the α helices in eIF2B α . In addition, the side chain of NSs H36 and the backbone carbonyl of NSs T35 both contact eIF2B δ R321. The side chain of NSs D37 also forms an ionic interaction with eIF2B δ R321, although the distance is close to 4.0 Å, suggesting a weak interaction. These three amino acids account for the only interactions with eIF2B δ (Fig. 5c).

To validate the functional importance of the eIF2B α -facing aromatic fingers, we mutated them in pairs or singly to alanines (Y5A/F7A, Y79A/F80A, and F33A) and stably expressed these NSs variants in the dual ISR reporter cells. The point mutations did not compromise NSs stability and, as with WT NSs, did not affect eIF2 or eIF2B subunit levels (Fig. 6a). Upon stress, eIF2 α became phosphorylated in all cell lines, but only in cells expressing WT NSs::FLAG was ATF4 translation blunted (Fig. 6a). A similar picture emerged from analysis of the fluorescent ISR reporter signals. Whereas wild-type NSs inhibited the translation of ATF4 and maintained general translation at roughly normal levels, all the point mutants tested broke the NSs’ function as an ISR evader (Fig. 6b). All 5 eIF2B α -facing aromatic fingers thus appear critical for NSs binding to eIF2B.

We additionally assessed the importance of the eIF2B δ -facing residues – generating stable lines with alanine mutations (H36A and D37A). As we saw with mutation of the aromatic fingers, neither H36A nor D37A impaired NSs translation or impacted eIF2 or

266 eIF2B subunit levels, but ISR evasion as monitored by ATF4 translation became
 267 compromised (Fig. 6c). Notably, NSs::FLAG (H36A) displayed an intermediate
 268 phenotype in the ATF4 and general translation reporter assays, suggesting that while
 269 this mutation compromises NSs binding it does not appear to entirely break the
 270 interaction (Fig. 6d). In contrast, NSs::FLAG (D37A) expressing cells appear unable to
 271 resist ISR activation. Although the structure suggests only a mild ionic interaction
 272 between NSs D37 and eIF2B δ R321, we reason the D37A mutation might not only break
 273 the ionic interaction, but also potentially alter the conformation of the loop. As a result,
 274 V38 would move, disrupting its stacking with M6, an amino acid next to two aromatic
 275 fingers (Y5 and F7) (Extended Data Fig. 7). Thus, changes to D37 and H36 could result
 276 in the repositioning of the eIF2B α -facing aromatic fingers, leading to a complete loss of
 277 NSs interaction with eIF2B. Together, these data provide a rationale for NSs' potent and
 278 selective binding to only fully assembled eIF2B($\alpha\beta\delta\gamma\epsilon$)₂ decamers.

Discussion

As one of the strategies in the evolutionary arms race between viruses and the host cells they infect, mammalian cells activate the ISR to temporarily shut down translation, thus preventing the synthesis of viral proteins. Viruses, in turn, have evolved ways to evade the ISR, typically by disarming the PKR branch through countermeasures that lead to decreased levels of eIF2-P, thus allowing translation to continue. In this study, we show that SFSV expresses a protein (NSs) that allows it to evade not just PKR-mediated ISR activation, but all four branches of the ISR, through a mechanism that exploits the conformational flexibility of eIF2B. NSs is an antagonistic mimic of eIF2B's inhibitor eIF2-P, deploying an overlapping binding site. Whereas eIF2-P shifts eIF2B to its inactive I-State conformation by closing the angle between the eIF2B α and eIF2B δ subunits, NSs engages the enzyme to opposite effect, binding to an overlapping site with eIF2-P but preserving the angle between eIF2B α and eIF2B δ and locking it into its active A-State conformation.

Previously, we and others showed that the GEF activity of eIF2B is modulated conformationally: eIF2B's substrate (eIF2) binding stabilizes it in the A-state, whereas its inhibitor (eIF2-P) binding induces a hinge motion between the two tetrameric halves, resulting in a conformation that cannot engage the substrate optimally (I-state) [5, 6]. Our structure shows that NSs antagonizes the endogenous inhibitor (eIF2-P) by directly competing it off and stabilizing eIF2B in the active conformation. Thus, while NSs binds to the inhibitor-binding site, it does not induce the conformational change that the inhibitor binding induces. This mechanism is reminiscent of the antagonistic inhibition of GPCRs, such as the β adrenergic receptors, where binding of an agonist ligand shifts the receptor to its active conformation, whereas binding of an antagonist ligand occupies an overlapping but not identical binding site that lacks contacts required to induce the activating conformational change [32-35]. NSs, however, is an antagonist of an inhibitor (eIF2-P). Thus, by inhibiting an inhibition, it actually works as an eIF2B activator under conditions where eIF2-P is present and the ISR is induced.

In its ability to modulate eIF2B, NSs is not unique among viral proteins. The beluga whale coronavirus (Bw-CoV) protein AcP10 likewise allows evasion of the host cell ISR

by interacting with eIF2B, as does the picornavirus AivL protein [23]. It was suggested that AcP10 makes contacts with eIF2B α and eIF2B δ , akin to NSs, and hence may act through a similar mechanism by antagonizing eIF2-P, although no structural information is yet available. By primary sequence comparison, AcP10, AivL, and NSs show no recognizable homology with one another, indicating that viruses have evolved at least three – and likely more – different ways to exploit the eIF2 α -P binding site on eIF2B to shut off the ISR. Therefore, inhibiting the eIF2B-eIF2-P interaction through the antagonistic mimicry of eIF2-P could also be a general strategy used by many viruses.

Our structure and mutational analysis suggest that the binding of different parts of NSs to eIF2B occurs in a highly cooperative manner. While the amino acids facing eIF2B δ do not seem to make sufficiently intimate contacts to provide a significant contribution to the enthalpic binding energy, changing them disrupts binding. It is plausible that the contacts of NSs with eIF2B δ allow the optimal positioning of the aromatic fingers through allosteric communications between the loops and thus license NSs for tight binding.

The structure of the eIF2B-NSs complex reveals a previously unknown site on eIF2B that is potentially druggable. Unlike ISRIB, which activates eIF2B through binding to a narrow pocket at the center of eIF2B and stapling the two tetrameric halves together at a precise distance and angle, NSs binds to a different interface on the opposite side of the protein. With ISRIB-derivatives showing extreme promise to alleviate cognitive dysfunction in animal studies of various neurological disorders and recently progressing into the clinic for Phase I human trials, developing therapeutics that modulate the ISR has never been more relevant [36].

Across phleboviruses, all characterized members of the family of related NSs proteins also counteract the host's interferon response [25, 26]. For RVFV, this functionality is contained within the structurally conserved C-terminal domain, which nonetheless varies quite heavily in sequence space [27, 28, 37, 38]. A strict functional conservation does not appear to be the case for the N-terminal domain. Although this domain serves to evade PKR in some phleboviruses such as RVFV and SFSV, it accomplishes it through entirely different means: degradation of PKR in RVFV and antagonism of eIF2-P binding to eIF2B in SFSV [19, 29]. The NSs is thus a bispecific molecule – a multitool of sorts. The C-terminal domain may serve as a scaffold containing a core functionality upon

which the N-terminal domain may be free to evolve, exploring diverse functionalities and mechanisms. It is exciting to speculate whether anti-PKR properties of the N-terminal domain, as we identified for SFSV NSs, are commonly found across phleboviruses and whether still other PKR evasion strategies can be found.

Aberrant ISR activation underlies many neurological disorders (Traumatic Brain Injury, Down's Syndrome, Alzheimer's Disease, Amyotrophic Lateral Sclerosis), as well as certain cancers (metastatic prostate cancer) [36, 39-43]. Virotherapy, where viruses are used as a therapeutic agent for particular diseases, has seen the most success in the realm of cancer treatment where the infection either directly attacks cancer cells (oncolytic virotherapy) or serves to activate host defenses which target virus and cancer alike [44, 45]. Indeed, decades of evidence have shown that cancer patients that experience an unrelated viral infection can show signs of improvement, paving the way for the generation of genetically engineered oncolytic viruses that have only just received FDA approval in the last decade [46, 47]. With our ever-growing understanding of diverse host-virus interactions, a whole host of new virotherapies are imaginable that can exploit the evolved functionalities of viral proteins such as the NSs.

Figures

Fig. 1: The SFSV NSs is a pan-ISR inhibitor

(a) Western blot of K562 cell extracts. Loading of all lanes was normalized to total protein. (b-d) ATF4 and General Translation reporter levels as monitored by flow cytometry. Trimethoprim, which is necessary to stabilize the ecDHFR::mScarlet-i and ecDHFR::mNeonGreen translation reporters, was at 20 μ M for all conditions. (b) Samples after 3 h of thapsigargin and trimethoprim treatment. (c) Samples after 3 h of oligomycin and trimethoprim treatment. (d) Samples after 4 h of glutamine deprivation, L-methionine sulfoximine, and trimethoprim treatment. For (a), PERK and GAPDH, PKR and eIF2 α , and eIF2B ϵ and NSs (FLAG) are from the same gels, respectively. eIF2B δ is from its own gel. For (b-d), biological replicates: n = 3. All error bars represent s.e.m.

Fig. 2: NSs specifically binds to eIF2B(αβγδε)₂ decamers

(a) Size exclusion chromatogram (Superdex 200 Increase 10/300 GL) during NSs purification from Expi293 cells. (b) Coomassie Blue staining of purified NSs. (c) Western blot of purified protein recovered after incubation with eIF2B(αβγδε)₂, eIF2Bβδγϵ, or eIF2Bα₂ immobilized on Anti-protein C antibody conjugated resin. For eIF2B(αβγδε)₂ and eIF2Bα₂, eIF2Bα was protein C tagged. eIF2Bβ was protein C tagged for eIF2Bβδγϵ. (d-f) SPR of immobilized (d) eIF2B(αβγδε)₂, (e) eIF2Bβδγϵ, and (f) eIF2Bα₂ binding to NSs. For eIF2B(αβγδε)₂ and eIF2Bβδγϵ, eIF2Bβ was Avi-tagged and biotinylated. For eIF2Bα₂, eIF2Bα was Avi-tagged and biotinylated. Concentration series (125 nM, 62.5 nM, 31.25 nM, 15.625 nM) consistent across all 3 conditions. For (c), eIF2Bβ and eIF2Bα, and eIF2Bδ and NSs (6xHIS) are from the same gels, respectively. eIF2Bε is from its own gel.

Fig. 3: NSs grants ISR evasion by antagonizing eIF2α-P binding to eIF2B

(a) GEF activity of eIF2B as assessed by BODIPY-FL-GDP exchange. eIF2B(αβδγϵ)₂ at 10 nM throughout. $t_{1/2}$ = 6.3 min (No eIF2α-P), 6.2 min (2 μM eIF2α-P + 100 nM NSs), 9.2 min (2 μM eIF2α-P + 25 nM NSs), and 13.4 min (2 μM eIF2α-P + 100 nM NSs). **(b)** Plot of fluorescence polarization signal before (*red*) and after incubation of FAM-ISRIB (2.5 nM) with 100 nM eIF2B(αβδγϵ)₂ (*black*) or 100 nM eIF2B(αβδγϵ)₂ + 5.6 μM eIF2α-P (*blue*) and varying concentrations of NSs. **(c)** Western blot of purified protein recovered after incubation with eIF2B(αβδγϵ)₂ immobilized on Anti-protein C antibody conjugated resin. eIF2Bα was protein C tagged.

For (c), eIF2Bε and eIF2α-P, eIF2Bβ and eIF2Bα, and eIF2Bδ and NSs (6xHIS) are from the same gels, respectively. For (a-b), biological replicates: $n = 3$. All error bars represent s.e.m.

Fig. 4: Overall architecture of the eIF2B-NSs complex

(a) Cryo-EM map of the eIF2B-NSs complex. (b) Overlay of the apo eIF2B structure (PDB ID: 7L70) and the eIF2B-NSs structure shows that the overall conformation of eIF2B is nearly identical between the NSs-bound state and the apo state. (c) Overlay of the eIF2B-eIF2α-P complex structure (PDB ID: 6O9Z) and the eIF2B-NSs structure shows a 7.5° hinge movement between the two eIF2B halves. (d) and (e) Both NSs and eIF2α-P bind to eIF2B at the cleft between eIF2Bα and eIF2Bδ. (d) NSs mainly contacts eIF2Bα, whereas (e) eIF2α-P makes extensive contacts to both eIF2Bα and eIF2Bδ. (f) Comparison between the surfaces of NSs and eIF2α-P showing a significant overlay between the two.

Fig. 5: NSs latches on to eIF2B with its aromatic fingers

(a) Surface representation of NSs showing that it grips the alpha helices of eIF2Bα. **(b)** NSs extends five aromatic amino acids in three short loops to contact eIF2Bα. They contact helices α3 and α4 of eIF2Bα. The backbone of T35 and the side chains of H36 and D37 of NSs make contact with eIF2Bδ **(c)** Zoomed in view of panel b showing the interaction between H36 and D37 with eIF2Bδ. **(d)** and **(e)** Zoomed-in view of panel b showing the detailed interactions between the five main aromatic amino acids and eIF2Bα. Each polar-polar or cation-π interaction is denoted by a dashed line. NSs is colored in gold and eIF2B in blue.

Fig. 6: All 5 aromatic fingers are required for NSs evasion of the ISR

(a and c) Western blot of K562 cell extracts 3 h after treatment with 50 nM thapsigargin. Loading of all lanes was normalized to total protein. **(b and d)** ATF4 and General Translation reporter levels as monitored by flow cytometry after 3 h of thapsigargin and trimethoprim (20 μM) treatment.

For (a), ATF4 and eIF2α, eIF2Bε and NSs (FLAG), and eIF2Bδ and eIF2α-P are from the same gels, respectively. GAPDH is from its own gel. For (c), ATF4 and GAPDH, eIF2Bε and NSs (FLAG), and eIF2Bδ and eIF2α-P are from the same gels, respectively. eIF2α is from its own gel. For (b), biological replicates: n = 3. For (d), biological replicates: n = 4. All error bars represent s.e.m.

Fig. 7: Model for regulation of eIF2B activity.

Like the small molecule ISRIB and the substrate eIF2, NSs binds to and stabilizes the active, “wings up” conformation of eIF2B (A-State). eIF2-P induces the inhibited “wings down” conformation of eIF2B (I-State).

Extended Data

Empty Vector

NSs::FLAG

FLAG::NSs

Extended Data Fig. 1: Design of NSs expression constructs

A schematic of the NSs expression constructs stably integrated (lentivirus) into the genome.

Extended Data Fig. 2: Effect of NSs alone on eIF2B nucleotide exchange

GEF activity of eIF2B as assessed by BODIPY-FL-GDP exchange. BODIPY-FL-GDP fluorescence increases when bound to protein. $t_{1/2} = 3.6$ min, s.e.m. = 0.5 min (No NSs) and 3.4 min, s.e.m. = 0.5 min (100 nM NSs). eIF2B($\alpha\beta\delta\gamma\epsilon$)₂ at 10 nM throughout. Biological replicates: n = 2.

Extended Data Fig. 3: Cryo-EM data analysis flow

454 (a) Representative micrograph of the eIF2B-NSs sample. (b) Data processing scheme
 455 for reconstruction of eIF2B-NSs assembly. (c) Fourier shell correlation (FSC) plots of the
 456 3D reconstructions of the eIF2B-NSs complex masked (orange), unmasked (blue) (d)
 457 Orientation angle distribution of the eIF2B-NSs complex reconstruction. (e) Local
 458 resolution map of the eIF2B-NSs complex showing that the N-terminal region of NSs that
 459 contacts eIF2B is well-resolved, and the C-terminal region of NSs that faces the solution
 460 is more dynamic. (f) Electron microscopy maps of different regions of the NSs structure
 461 in the eIF2B-NSs complex showing the quality of the data and the fit of the model.

		Aromatic fingers		
RVFV	-----MDYFPVISVDLQSGRRVVSVEYFRGDGPPRIPYSMVGPCCVFLMHHRPSHEVRLR	55		
SFSV	MNSQYMFDPAINIDVRCHRLSSVSIVAYNKFHTHDVSTYEHCEIPLEKLRLGFGRNS	60		
	* :*.*. :*: : * : *.*. : * * : * : * .. *			
RVFV	FSDFYNVGEFPYRVGLGDFASNVAPPPAKPFQRLIDLIGHMTLSDF--TRFPNLKEAISW	113		
SFSV	LADFYSLGELPASWGPACYFSSVKPM-MYTFQGMASDLRFDLTSFSRKGLPNVLKALSW	117		
	:***. :*: * . : *. * * ** : . :*: * : * . :*: :*: *			
RVFV	PLGEPSLAFFDLSSSTRVHRNDDIRRDQIATLAMRSCKITNDLEDSFVGLHRMIATEAILR	173		
SFSV	PLGIPDCEIFSICSDRFVRGLQTRDQ-LMSYILRM-GDSHSLDECIVQAHKKILQEARRL	177		
	*** *. :*. :* *. *. : * : : : * :*. :*: * : * *			
RVFV	GIDLCLLPGFDLMEVAHVQCVRLQLAAKEDISNAVVPNSALIVLMEESLMLRSSLPMM	233		
SFSV	GLSDEHYNGYDLFREIGSLVCLRLINAEPFDTASSGEALDVRTVIRSYRASDPSTGLTEY	237		
	*:. * :*: * : : * :*: * * : : .. * : . * : :			
RVFV	GRNNWIPVIPPIPDVEMESEEESDDDDGFVEVD	265		
SFSV	GNSLWTPIHSHVDEN----DESSSDSDF----	261		
	*.. * *: : : :*. *. *. *			

Extended Data Fig. 4: Primary sequence alignment of the SFSV NSs and the RVFV NSs

Alignment shows that the primary sequence between the two NSs shares 43.2% similarity and most of the aromatic finger amino acids (in cyan boxes) in the SFSV NSs are not conserved in the RVFV NSs.

Extended Data Fig. 5: Structural comparison between the SFSV NSs and the RVFV NSs

(a) Overlay of the RVFV NSs C-terminal domain structure (PDB ID: 5000, chain A) to the SFSV NSs showing that the C-terminal domain of the two NSs share similar overall structures. However, it is the N-terminal domain that forms direct contact with eIF2B. **(b)** Zoomed in view of panel (a) showing the structural similarity between the C-terminal domains of the two NSs.

Extended Data Fig. 6: Effect of NSs truncations on protein function

(a) ATF4 and (b) General Translation reporter levels as monitored by flow cytometry after 3 h of thapsigargin (100 nM) and trimethoprim (20 μ M) treatment. ATF4 and General Translation reporter levels are shown for the population of BFP+ cells (that is, cells that have stably integrated the NSs expression constructs). NSs truncation abolishes its ISR evasion functionality, either by destabilizing protein synthesis or, more specifically, the interaction with eIF2B.

Extended Data Fig. 7: Cooperative binding of NSs loops

Zoomed in view of the NSs loops interaction with eIF2B. The conformation of the eIF2Bδ-facing amino acids (H36 and D37) could affect the positioning of V38, which forms hydrophobic stacking with M6. This stacking interaction may be important for the optimal positioning of Y5 and F7, the two main aromatic fingers facing eIF2Bα, thus contributing to NSs-eIF2B binding.

Extended Data Fig. 8: Schematic overview of the aromatic fingers

(a) Cartoon representation of the NSs aromatic fingers interacting with eIF2Bα. A koala was chosen to illustrate this interaction as their hands have three fingers and two opposable thumbs that grab onto branches from opposite sides in a geometry similar to how NSs grabs onto eIF2Bα **(b)** Zoomed out view of panel a.

Extended Data Table 1

Structure	eIF2B-NSs complex
Data collection	
Microscope	Titan Krios
Voltage (keV)	300
Nominal magnification	105000x
Exposure navigation	Image shift
Electron dose (e ⁻ Å ⁻²)	67
Dose rate (e ⁻ /pixel/sec)	8
Detector	K3 summit
Pixel size (Å)	0.835
Defocus range (µm)	0.6-2.0
Micrographs	2143
Reconstruction	
Total extracted particles (no.)	1055439
Final particles (no.)	137093
Symmetry imposed	C1
FSC average resolution, masked (Å)	2.6
FSC average resolution, unmasked (Å)	3.7
Applied B-factor (Å)	76.2
Reconstruction package	Cryosparc 2.15
Refinement	
Protein residues	3661
Ligands	0
RMSD Bond lengths (Å)	0.002
RMSD Bond angles (°)	0.606
Ramachandran outliers (%)	0.06
Ramachandran allowed (%)	5.46
Ramachandran favored (%)	94.49
Poor rotamers (%)	6.25
CaBLAM outliers (%)	2.92
Molprobtity score	2.38
Clash score (all atoms)	7.28
B-factors (protein)	104.43
B-factors (ligands)	N/A
EMRinger Score	3.02
Refinement package	Phenix 1.17.1-3660-000

Extended Data Table 2

Plasmid	Description	Antibiotic
pMS113	NSs::6xHIS for Expi293 expression / purification	Ampicillin
pMS085	Empty Vector for lentiviral integration	Ampicillin
pMS110	NSs::FLAG for lentiviral integration	Ampicillin
pMS111	FLAG::NSs for lentiviral integration	Ampicillin
pMS119	Truncated NSs (aa 1-89) for lentiviral integration	Ampicillin
pMS120	Truncated NSs (aa 1-137) for lentiviral integration	Ampicillin
pMS121	Truncated NSs (aa 1-155) for lentiviral integration	Ampicillin
pMS122	Truncated NSs (aa 1-185) for lentiviral integration	Ampicillin
pMS123	Truncated NSs (aa 1-213) for lentiviral integration	Ampicillin
pMS127	NSs::FLAG (Y5A/F7A) for lentiviral integration	Ampicillin
pMS128	NSs::FLAG (Y79A/F80A) for lentiviral integration	Ampicillin
pMS129	NSs::FLAG (F33A) for lentiviral integration	Ampicillin
pMS132	NSs::FLAG (H36A) for lentiviral integration	Ampicillin
pMS134	NSs::FLAG (D37A) for lentiviral integration	Ampicillin
pMS001	<i>E. coli</i> expression plasmid for eIF2B δ and Avi-tagged eIF2B β	Chloramphenicol
pMS003	<i>E. coli</i> expression plasmid for eIF2B δ and Protein C-tagged eIF2B β	Chloramphenicol
pMS026	<i>E. coli</i> expression plasmid for Avi-tagged eIF2B α	Ampicillin

Extended Data Table 3

Antibody Target	Host	Dilution	Manufacturer / Catalog #	Blocking Conditions
GAPDH	Rabbit	1/2000	Abcam / ab9485	TBS-T + 3% BSA
eIF2B α	Rabbit	1/1000	ProteinTech / 18010-1-AP	TBS-T + 3% milk
eIF2B β	Rabbit	1/1000	ProteinTech / 11034-1-AP	TBS-T + 3% milk
eIF2B δ	Rabbit	1/1000	ProteinTech / 11332-1-AP	TBS-T + 3% milk
eIF2B ϵ	Mouse	1/1000	Santa Cruz Biotechnology / sc-55558	PBS-T + 3% milk
ATF4	Rabbit	1/1000	Cell Signaling / 11815S	PBS-T + 3% milk
eIF2 α -P	Rabbit	1/1000	Cell Signaling / 9721S	PBS-T + 1% BSA
eIF2 α	Rabbit	1/1000	Cell Signaling / 5324S	PBS-T + 3% milk
6xHIS	Goat (directly conjugated to HRP)	1/1000	Abcam / ab1269	TBS-T + 5% milk
FLAG	Mouse	1/1000	Sigma / F1804-1MG	PBS-T + 3% milk
PKR	Mouse	1/1000	BD Transduction Laboratories / 610764	TBS-T + 3% milk
PERK	Rabbit	1/1000	Cell Signaling / 3192S	TBS-T + 3% milk

Materials and Methods

Cloning of NSs expression plasmids

The NSs::6xHIS Expi293 expression plasmid for transient transfection was generated using In-Fusion HD cloning. The SFSV NSs sequence [29] was inserted into the pXSN vector backbone and a 6xHIS tag was added at the C-terminus. The various NSs overexpression plasmids for stable lentiviral integration were generated using In-Fusion HD cloning. The SFSV NSs sequence was inserted into the pDBR vector backbone and a FLAG tag was added at the C-terminus (pMS110, pMS127, pMS128, pMS129, pMS130, pMS131, pMS132, pMS133) or N-terminus (pMS111). The various NSs truncations did not have a FLAG tag (pMS119, pMS120, pMS121, pMS122, pMS123). An empty vector control plasmid with no NSs insertion was also generated (pMS085). An IRES followed by the puromycin resistance gene, a T2A self-cleaving peptide, and the BFP sequence allows for selection based on antibiotic resistance or BFP signal (what was used in this study) (Extended Data Fig. 1). Full plasmid details are shown in Extended Data Table 2.

Cloning of tagged human eIF2B expression plasmids

eIF2B2 (encoding eIF2B β) and *eIF2B4* (encoding eIF2B δ) had previously been inserted into sites 1 and 2 of pACYCDuet-1, respectively (pJT073) [8]. In-Fusion HD cloning (TakaraBio) was used to edit this plasmid further and insert an Avi tag (GLNDIFEAQKIEWHE) or a Protein C tag (EDQVDPRLIDGK) at the N-terminus of *eIF2B2*, immediately following the pre-existing 6xHIS tag (pMS001 and pMS003). *eIF2B1* (encoding eIF2B α) had previously been inserted into site 1 of pETDuet-1 (pJT075) [8]. In-Fusion HD cloning was used to edit this plasmid further and insert an Avi tag at the N-terminus of *eIF2B1*, immediately following the pre-existing 6xHIS tag (pMS026). The Avi tag allows selective, single, and complete biotinylation of the tagged protein.

Generation of stable NSs-expressing cells in an ISR reporter cell line

Our previously generated dual ISR reporter K562 cells expressing a stably integrated ATF4 reporter (pMS086), general translation reporter (pMS078), and dCas9-KRAB was used as the parental line [5]. The various NSs overexpression constructs (Extended Data Table 2) were integrated using a lentiviral vector. Vesicular stomatitis virus (VSV)-G pseudotyped lentivirus was prepared using standard protocols and 293METR

packaging cells. Viral supernatants were filtered (0.45 µm low protein binding filter unit (EMD Millipore)) and concentrated 10-20-fold (Amicon Ultra-15 concentrator with a 100,000-dalton molecular mass cutoff). Concentrated supernatant was then used the same day or frozen for future use. For spinfection, approximately 1,000,000 K562 cells were mixed with concentrated lentivirus and fresh media (RPMI containing 4.5 g/l glucose and 25 mM HEPES supplemented with 10% FBS, 2 mM L-alanyl-L-glutamine (Gibco GlutaMAX), and penicillin/streptomycin), supplemented with polybrene to 8 µg/ml, brought to 1.5 mL in a 6-well plate, and centrifuged for 1.5 h at 1000 g. Cells were then allowed to recover and expand for ~1 week before sorting on a Sony SH800 cytometer to isolate cells that had integrated the reporter. Roughly 100,000 BFP positive cells (targeting the highest 1-3% of expressers) were then sorted into a final pooled population and allowed to recover and expand. Cells expressing NSs truncations (pMS119-pMS123) were not sorted and instead analyzed as a polyclonal population, gating for BFP positive cells during data analysis.

Western Blotting

Western blotting was performed as previously described [5]. In brief, approximately 1,000,000 cells of the appropriate cell type were drugged as described in individual assays and then pelleted, washed, pelleted again, and resuspended in lysis buffer. Cells were then rotated for 30 min at 4 °C and then spun at 12,000 g for 20 min to pellet cell debris. Protein concentration was measured using a bicinchoninic acid assay (BCA assay) and within an experiment, total protein concentration was normalized to the least concentrated sample. Equal protein content for each condition (targeting 10 µg) was run on 10% Mini-PROTEAN TGX precast protein gels (Biorad). After electrophoresis, samples were transferred onto a nitrocellulose membrane. Primary antibody / blocking conditions for each protein of interest are outlined in Extended Data Table 3. Membranes were developed with SuperSignal West Dura (Thermo Fisher Scientific). Developed membranes were imaged on a LI-COR Odyssey gel imager for 0.5-10 min depending on band intensity.

ATF4 / general translation reporter assays

ISR reporter cells (at ~500,000 / ml) were co-treated with varying combinations of drugs (20 µM trimethoprim plus one of the following: thapsigargin, oligomycin, or glutamine deprivation (and no FBS) + L-methionine sulfoximine) and incubated at 37 °C until the

appropriate timepoint had been reached. At this time, the plate was removed from the incubator and samples were incubated on ice for 10 min. Then ATF4 (mNeonGreen) and General Translation (mScarlet-i) reporter levels were monitored using a high throughput sampler (HTS) attached to a BD FACSCelesta cytometer. Data was analyzed in FlowJo version 10.6.1, and median fluorescence values for both reporters were exported and plotted in GraphPad Prism 8. No BFP positive sorting was performed on the lines expressing NSs truncations. For analysis of these samples, BFP positive cells were gated in FlowJo and analysis performed on this population. Where appropriate, curves were fit to log[inhibitor] versus response function with variable slope.

Purification of human eIF2B subcomplexes

Human eIFB α_2 (pJT075), Avi-tagged eIFB α_2 (pMS026), protein C-tagged eIFB α_2 (pMS027), eIF2B $\beta\gamma\delta\epsilon$ (pJT073 and pJT074 co-expression), Avi-tagged eIF2B $\beta\gamma\delta\epsilon$ (pMS001 and pJT074 co-expression), and ProteinC-tagged eIF2B $\beta\gamma\delta\epsilon$ (pMS003 and pJT074 co-expression) were purified as previously described [8] with a minor modification for purification of the Avi-tagged species. After running samples over a MonoQ HR 10/10 column the eluted fractions were combined and concentrated to a target concentration of 40 μ M. The sample was then incubated at 4 °C overnight according to manufacturer's instructions with 2.5 μ g BirA for every 10 nmol substrate, 10mM ATP, 50 μ M d-biotin, and 100mM Mg(OAc) $_2$ in a 50 mM bicine buffer, pH 8.3 (Avidity BirA biotin-protein ligase standard reaction kit). Incubation with BirA yields selective and efficient biotinylation of Avi-tagged species. After the biotinylation reaction, purification of biotinylated species proceeded as previously described.

All eIF2B($\alpha\beta\gamma\delta\epsilon$) $_2$ used throughout was assembled by mixing purified eIF2B $\beta\gamma\delta\epsilon$ and eIF2B α_2 (either tagged or untagged versions as needed) at the appropriate molar ratios.

Purification of human eIF2 $\alpha\beta\gamma$ heterotrimer and eIF2 α -P

Human eIF2 was purified as previously described [48]. This material was a generous gift of Calico Life Sciences LLC. The purification of human eIF2 α -P was performed as previously described [5].

Purification of NSs::6xHIS

We used the pMS113 construct to express and purify NSs::6xHIS. Expi293T cells (ThermoFisher) were transfected with the NSs construct per the manufacturer's instructions for the MaxTiter protocol and harvested 5 days after transfection. Cells were pelleted (1000 g, 4 min) and resuspended in Lysis Buffer (130 mM KCl, 2.5 mM MgCl₂, 25 mM HEPES-KOH pH 7.4, 2 mM EGTA, 1% triton, 1mM TCEP, 1x cOmplete protease inhibitor cocktail (Roche)). Cells were then incubated for 30 min at 4 °C and then spun at 30,000 g for 1 h to pellet cell debris. Lysate was applied to a 5 ml HisTrap HP column (GE Healthcare) equilibrated in Buffer A (20 mM HEPES-KOH, pH 7.5, 200 mM KCl, 5 mM MgCl₂, 15mM imidazole) and then eluted using a gradient of Buffer B (20 mM HEPES-KOH, pH 7.5, 200 mM KCl, 5 mM MgCl₂, 300mM imidazole). NSs::6xHIS was concentrated using a 10 kDa MWCO spin concentrator (Amicon) and further purified by size exclusion chromatography over a Superdex 200 Increase 10/300 GL column (GE Healthcare) in Elution Buffer (20 mM HEPES, pH 7.5, 200 mM KCl, 5mM MgCl₂, 1mM TCEP, and 5% Glycerol). The resulting fractions were pooled and flash frozen in liquid nitrogen

***In vitro* NSs/eIF2α-P immunoprecipitation**

Varying combinations of purified eIF2α-P, NSs::6xHIS, eIF2B(αβδγϵ)₂, eIF2Bβδγϵ, and eIF2Bα₂ were incubated (with gentle rocking) with Anti-protein C antibody conjugated resin (generous gift from Aashish Manglik) in Assay Buffer (20 mM HEPES-KOH, pH 7.5, 150 mM KCl, 5 mM MgCl₂, 1mM TCEP, 1 mg/ml bovine serum albumin (BSA), 5mM CaCl₂). After 1.5 h the resin was pelleted by benchtop centrifugation and the supernatant was removed. Resin was washed 3x with 1 mL of ice cold Assay Buffer before resin was resuspended in Elution Buffer (Assay Buffer with 5 mM EDTA and 0.5 mg/mL protein C peptide added) and incubated with gentle rocking for 1 h. The resin was then pelleted and the supernatant was removed. Samples were analyzed by Western Blotting as previously described.

GDP exchange assay

in vitro detection of GDP binding to eIF2 was performed as previously described [5, 8]. The only modification was addition of NSs in certain conditions as indicated. In brief, purified eIF2 (100 nM) was incubated with 100 nM BODIPY-FL-GDP (Thermo Fisher Scientific) in assay buffer (20 mM HEPES-KOH, pH 7.5, 100 mM KCl, 5 mM MgCl₂, 1 mM TCEP, and 1 mg / ml BSA) to a volume of 18 µl in 384 square-well black-walled,

clear-bottom polystyrene assay plates (Corning). The GEF mix was prepared by incubating a 10x solution of eIF2B($\alpha\beta\gamma\delta\epsilon$)₂ with or without 10x solutions of eIF2 α -P and / or NSs. To compare nucleotide exchange rates, the 10x GEF mixes were spiked into the 384-well plate wells with a multi-channel pipette, such that the resulting final concentration of eIF2B($\alpha\beta\gamma\delta\epsilon$)₂ was 10 nM and the final concentration of other proteins and drugs are as indicated in the figures. Fluorescence intensity was recorded every 10 s for 30-60 min using a Clariostar PLUS (BMG LabTech) plate reader (excitation wavelength: 497 nm, bandwidth 14 nm, emission wavelength: 525 nm, bandwidth: 30 nm). Data were fit to a first-order exponential and plotted in GraphPad Prism 8.

FAM-ISRIB binding assay

All fluorescence polarization measurements were performed as previously described [5]. In brief, 20 μ l reactions were set up with 100 nM eIF2B($\alpha\beta\gamma\delta\epsilon$)₂ + 2.5 nM FAM-ISRIB (Praxis Bioresearch) in FP buffer (20 mM HEPES-KOH pH 7.5, 100 mM KCl, 5 mM MgCl₂, 1 mM TCEP) and measured in 384-well non-stick black plates (Corning 3820) using the ClarioStar PLUS (BMG LabTech) at room temperature. Prior to reaction setup, eIF2B($\alpha\beta\gamma\delta\epsilon$)₂ was assembled in FP buffer using eIF2B $\beta\gamma\delta\epsilon$ and eIF2B α_2 in 2:1 molar ratio for 1 h at room temperature. FAM-ISRIB was first diluted to 2.5 μ M in 100% NMP prior to dilution to 50 nM in 2% NMP and then added to the reaction. For titrations with NSs, dilutions were again made in FP buffer, and the reactions with eIF2B, FAM-ISRIB, and these dilutions +/- eIF2 α -P were incubated at 22 °C for 30 min prior to measurement of parallel and perpendicular intensities (excitation: 482 nm, emission: 530 nm). Data were plotted in GraphPad Prism 8, and where appropriate, curves were fit to log[inhibitor] vs response function with variable slope.

Affinity determination by surface plasmon resonance

NSs affinity determination experiments were performed on a Biacore T200 instrument (Cytiva Life Sciences) by capturing the biotinylated eIF2B($\alpha\beta\gamma\delta\epsilon$)₂, eIF2B $\beta\gamma\delta\epsilon$, and eIF2B α_2 at ~100nM on a Biotin CAPture Series S sensor chip (Cytiva Life Sciences) to achieve maximum response (Rmax) of <100 response units (RUs) upon NSs binding. A molar equivalent of each eIF2B species was immobilized. 2-fold serial dilutions of purified NSs from 125 nM to 15.625 nM were flowed over the captured eIF2B complexes at 30 μ L / minute for 90 seconds followed by 600 seconds of dissociation flow. Following each cycle, the chip surface was regenerated with 3 M guanidine hydrochloride. A

running buffer of 20 mM HEPES-KOH, pH 7.5, 100 mM KCl, 5 mM MgCl₂, and 1 mM TCEP was used throughout. The resulting sensorgrams were fit to a 1:1 Langmuir binding model using the association then dissociation model in GraphPad Prism 8.0.

Sample preparation for cryo-electron microscopy

Decameric eIF2B($\alpha\beta\gamma\delta\epsilon$)₂ was prepared by incubating 20 μ M eIF2B $\beta\gamma\delta\epsilon$ with 11 μ M eIF2B α_2 in a final solution containing 20 mM HEPES-KOH, 200 mM KCl, 5 mM MgCl₂, and 1 mM TCEP. This 10 μ M eIF2B($\alpha\beta\gamma\delta\epsilon$)₂ sample was further diluted to 750 nM and incubated with 2.25 μ M NSs::6xHIS on ice for 1 h before plunge freezing. A 3 μ l aliquot of the sample was applied onto the Quantifoil R 1.2/1/3 400 mesh Gold grid and we waited for 30 s. A 0.5 μ l aliquot of 0.1-0.2% Nonidet P-40 substitute was added immediately before blotting. The entire blotting procedure was performed using Vitrobot (FEI) at 10 °C and 100% humidity.

Electron microscopy data collection

Cryo-EM data for the eIF2B-NSs complex was collected on a Titan Krios transmission electron microscope operating at 300 keV, and micrographs were acquired using a Gatan K3 direct electron detector. The total dose was 67 e⁻/Å², and 117 frames were recorded during a 5.9 s exposure. Data was collected at 105,000 x nominal magnification (0.835 Å/pixel at the specimen level), and nominal defocus range of -0.6 to -2.0 μ m.

Image processing

The micrograph frames were aligned using MotionCorr2 [49]. The contrast transfer function (CTF) parameters were estimated with GCTF [50]. Particles were picked in Cryosparc v2.15 using the apo eIF2B (EMDB: 23209) as a template. Particles were extracted using a 80-pixel box size [51], and classified in 2D [52]. Classes that showed clear protein features were selected and extracted for ab initio reconstruction followed by homogenous and heterogeneous refinement. Particles belonging to the best class were then re-extracted with a pixel size of 2.09 Å, and then subjected to nonuniform refinement, yielding a reconstruction of 4.25 Å. These particles were subjected to another round of heterogeneous refinement followed by nonuniform refinement to generate a consensus reconstruction consisting of the best particles. These particles were re-extracted at a pixel size of 0.835 Å. Then, CTF refinement was performed to

correct for the per-particle CTF as well as beam tilt. A final round of 2D classification followed by nonuniform refinement was performed to yield the final structure of 2.6 Å.

Atomic model building, refinement, and visualization

To build models for the eIF2B-NSs complex, the previously determined structures of the human eIF2B in its apo form (PDB ID: 7L70) was used as the starting model for the eIF2B part [5]. To build the NSs model, we first ran the structure prediction program RaptorX using the full-length NSs sequence [53]. The predicted structure is divided into two parts: the N-terminal domain predicted based on the structure of the RVFV NSs (PDB ID: 5O0O), and the C-terminal domain is predicted without a known PDB structure as a template [31]. The predicted full-length structure was docked into the EM density corresponding to the NSs in UCSF Chimera [54], and then subjected to rigid body refinement in Phenix [55]. The models were then manually adjusted in Coot [56] and then refined in phenix.real_space_refine [55] using global minimization, secondary structure restraints, Ramachandran restraints, and local grid search. Then iterative cycles of manual rebuilding in Coot and phenix.real_space_refine were performed. The final model statistics were tabulated using Molprobity [57]. Distances were calculated from the atomic models using UCSF Chimera. Molecular graphics and analyses were performed with the UCSF Chimera package [54]. UCSF Chimera is developed by the Resource for Biocomputing, Visualization, and Informatics and supported by NIGMS P41-GM103311.

Acknowledgments

We thank the Walter lab for helpful discussions throughout the course of this project; Calico Life Sciences LLC for a generous gift of purified eIF2 heterotrimer; Z Yu and D Bulkley of the UCSF Center for Advanced Cryo-EM facility, which is supported by NIH grants S10OD021741 and S10OD020054 and the Howard Hughes Medical Institute (HHMI); and we also thank the QB3 shared cluster for computational support.

Funding

This work was supported by generous support from Calico Life Sciences LLC (to PW); a generous gift from The George and Judy Marcus Family Foundation (To PW); the Belgian-American Educational Foundation (BAEF) Postdoctoral Fellowship (to MB), the Damon Runyon Cancer Research Foundation Postdoctoral fellowship (to LW); and the Jane Coffin Child Foundation Postdoctoral Fellowship (to RL). AF is a HHMI faculty scholar and a Chan Zuckerberg Biohub investigator. PW is an Investigator of the Howard Hughes Medical Institute.

Author Contributions

P.W. supervised the research. M.S., L.W., J.Z.C., and R.L. designed the experiments. M.S. performed all cloning. M.S., J.Z.C., R.L., and M.B. expressed and purified proteins. M.S. and J.Z.C. generated the cell lines. M.S. and J.Z.C. performed the flow cytometry experiments. M.S. performed the binding assays (SPR and bead immobilization). M.S., J.Z.C., and R.L. performed the nucleotide exchange assays. J.Z.C. and M.B. performed the FAM-ISRIB binding assay. M.S. performed all western blotting. L.W. performed cryo-EM sample preparation, data collection, processing, and model building. M.S., L.W., and P.W., prepared the manuscript, with input from all authors.

Competing Interests

PW is an inventor on U.S. Patent 9708247 held by the Regents of the University of California that describes ISRIB and its analogs. Rights to the invention have been licensed by UCSF to Calico. For the remaining authors, no competing financial interests exist.

Data Availability

All data available upon request.

References

1. Hinnebusch, A.G., *Translational regulation of GCN4 and the general amino acid control of yeast*. Annu Rev Microbiol, 2005. **59**: p. 407-50.
2. Guo, X., et al., *Mitochondrial stress is relayed to the cytosol by an OMA1-DELE1-HRI pathway*. Nature, 2020. **579**(7799): p. 427-432.
3. Dey, M., et al., *Mechanistic link between PKR dimerization, autophosphorylation, and eIF2alpha substrate recognition*. Cell, 2005. **122**(6): p. 901-13.
4. Shi, Y., et al., *Identification and characterization of pancreatic eukaryotic initiation factor 2 alpha-subunit kinase, PEK, involved in translational control*. Mol Cell Biol, 1998. **18**(12): p. 7499-509.
5. Schoof, M., et al., *eIF2B conformation and assembly state regulate the integrated stress response*. Elife, 2021. **10**.
6. Zyryanova, A.F., et al., *ISRIB Blunts the Integrated Stress Response by Allosterically Antagonising the Inhibitory Effect of Phosphorylated eIF2 on eIF2B*. Mol Cell, 2021. **81**(1): p. 88-103.e6.
7. Kashiwagi, K., et al., *Crystal structure of eukaryotic translation initiation factor 2B*. Nature, 2016. **531**(7592): p. 122-5.
8. Tsai, J.C., et al., *Structure of the nucleotide exchange factor eIF2B reveals mechanism of memory-enhancing molecule*. Science, 2018. **359**(6383).
9. Wortham, N.C., et al., *Analysis of the subunit organization of the eIF2B complex reveals new insights into its structure and regulation*. Faseb j, 2014. **28**(5): p. 2225-37.
10. Zyryanova, A.F., et al., *Binding of ISRIB reveals a regulatory site in the nucleotide exchange factor eIF2B*. Science, 2018. **359**(6383): p. 1533-1536.
11. Craddock, B.L. and C.G. Proud, *The alpha-subunit of the mammalian guanine nucleotide-exchange factor eIF-2B is essential for catalytic activity in vitro*. Biochem Biophys Res Commun, 1996. **220**(3): p. 843-7.
12. Kenner, L.R., et al., *eIF2B-catalyzed nucleotide exchange and phosphoregulation by the integrated stress response*. Science, 2019. **364**(6439): p. 491-495.
13. Gordiyenko, Y., J.L. Llcer, and V. Ramakrishnan, *Structural basis for the inhibition of translation through eIF2 phosphorylation*. Nat Commun, 2019. **10**(1): p. 2640.
14. Kashiwagi, K., et al., *Structural basis for eIF2B inhibition in integrated stress response*. Science, 2019. **364**(6439): p. 495-499.
15. Adomavicius, T., et al., *The structural basis of translational control by eIF2 phosphorylation*. Nat Commun, 2019. **10**(1): p. 2136.
16. Galabru, J. and A. Hovanessian, *Autophosphorylation of the protein kinase dependent on double-stranded RNA*. J Biol Chem, 1987. **262**(32): p. 15538-44.
17. Rosrio-Ferreira, N., et al., *The Central Role of Non-Structural Protein 1 (NS1) in Influenza Biology and Infection*. Int J Mol Sci, 2020. **21**(4).
18. Stasakova, J., et al., *Influenza A mutant viruses with altered NS1 protein function provoke caspase-1 activation in primary human macrophages*,

- 807 *resulting in fast apoptosis and release of high levels of interleukins 1beta and*
808 *18. J Gen Virol, 2005. 86(Pt 1): p. 185-195.*
- 809 19. Habjan, M., et al., *NSs protein of rift valley fever virus induces the specific*
810 *degradation of the double-stranded RNA-dependent protein kinase. J Virol,*
811 *2009. 83(9): p. 4365-75.*
- 812 20. Gale, M.J., Jr., M.J. Korth, and M.G. Katze, *Repression of the PKR protein kinase*
813 *by the hepatitis C virus NS5A protein: a potential mechanism of interferon*
814 *resistance. Clin Diagn Virol, 1998. 10(2-3): p. 157-62.*
- 815 21. Kawagishi-Kobayashi, M., et al., *Regulation of the protein kinase PKR by the*
816 *vaccinia virus pseudosubstrate inhibitor K3L is dependent on residues*
817 *conserved between the K3L protein and the PKR substrate eIF2alpha. Mol Cell*
818 *Biol, 1997. 17(7): p. 4146-58.*
- 819 22. Li, Y., et al., *ICP34.5 protein of herpes simplex virus facilitates the initiation of*
820 *protein translation by bridging eukaryotic initiation factor 2alpha (eIF2alpha)*
821 *and protein phosphatase 1. J Biol Chem, 2011. 286(28): p. 24785-92.*
- 822 23. Rabouw, H.H., et al., *Inhibition of the integrated stress response by viral*
823 *proteins that block p-eIF2-eIF2B association. Nat Microbiol, 2020. 5(11): p.*
824 *1361-1373.*
- 825 24. Hedil, M. and R. Kormelink, *Viral RNA Silencing Suppression: The Enigma of*
826 *Bunyavirus NSs Proteins. Viruses, 2016. 8(7).*
- 827 25. Ly, H.J. and T. Ikegami, *Rift Valley fever virus NSs protein functions and the*
828 *similarity to other bunyavirus NSs proteins. Virol J, 2016. 13: p. 118.*
- 829 26. Wuerth, J.D. and F. Weber, *Phleboviruses and the Type I Interferon Response.*
830 *Viruses, 2016. 8(6).*
- 831 27. Wuerth, J.D., et al., *NSs Protein of Sandfly Fever Sicilian Phlebovirus*
832 *Counteracts Interferon (IFN) Induction by Masking the DNA-Binding Domain of*
833 *IFN Regulatory Factor 3. J Virol, 2018. 92(23).*
- 834 28. Billecocq, A., et al., *NSs protein of Rift Valley fever virus blocks interferon*
835 *production by inhibiting host gene transcription. J Virol, 2004. 78(18): p.*
836 *9798-806.*
- 837 29. Wuerth, J.D., et al., *eIF2B as a Target for Viral Evasion of PKR-Mediated*
838 *Translation Inhibition. mBio, 2020. 11(4).*
- 839 30. Sidrauski, C., et al., *Pharmacological brake-release of mRNA translation*
840 *enhances cognitive memory. Elife, 2013. 2: p. e00498.*
- 841 31. Barski, M., et al., *Rift Valley fever phlebovirus NSs protein core domain*
842 *structure suggests molecular basis for nuclear filaments. Elife, 2017. 6.*
- 843 32. Kobilka, B.K., *Structural insights into adrenergic receptor function and*
844 *pharmacology. Trends Pharmacol Sci, 2011. 32(4): p. 213-8.*
- 845 33. Rasmussen, S.G., et al., *Structure of a nanobody-stabilized active state of the*
846 *β(2) adrenoceptor. Nature, 2011. 469(7329): p. 175-80.*
- 847 34. Rasmussen, S.G., et al., *Crystal structure of the β2 adrenergic receptor-Gs*
848 *protein complex. Nature, 2011. 477(7366): p. 549-55.*
- 849 35. Staus, D.P., et al., *Allosteric nanobodies reveal the dynamic range and diverse*
850 *mechanisms of G-protein-coupled receptor activation. Nature, 2016.*
851 *535(7612): p. 448-52.*

36. Chou, A., et al., *Inhibition of the integrated stress response reverses cognitive deficits after traumatic brain injury*. Proc Natl Acad Sci U S A, 2017. **114**(31): p. E6420-e6426.
37. Cyr, N., et al., *A Ω XaV motif in the Rift Valley fever virus NSs protein is essential for degrading p62, forming nuclear filaments and virulence*. Proc Natl Acad Sci U S A, 2015. **112**(19): p. 6021-6.
38. Sall, A.A., et al., *Variability of the NS(S) protein among Rift Valley fever virus isolates*. J Gen Virol, 1997. **78** (Pt 11): p. 2853-8.
39. Zhu, P.J., et al., *Activation of the ISR mediates the behavioral and neurophysiological abnormalities in Down syndrome*. Science, 2019. **366**(6467): p. 843-849.
40. Ma, T., et al., *Suppression of eIF2 α kinases alleviates Alzheimer's disease-related plasticity and memory deficits*. Nat Neurosci, 2013. **16**(9): p. 1299-305.
41. Atkin, J.D., et al., *Endoplasmic reticulum stress and induction of the unfolded protein response in human sporadic amyotrophic lateral sclerosis*. Neurobiol Dis, 2008. **30**(3): p. 400-7.
42. Nguyen, H.G., et al., *Development of a stress response therapy targeting aggressive prostate cancer*. Sci Transl Med, 2018. **10**(439).
43. Costa-Mattioli, M. and P. Walter, *The integrated stress response: From mechanism to disease*. Science, 2020. **368**(6489).
44. Harrington, K., et al., *Optimizing oncolytic virotherapy in cancer treatment*. Nat Rev Drug Discov, 2019. **18**(9): p. 689-706.
45. Russell, S.J., *RNA viruses as virotherapy agents*. Cancer Gene Ther, 2002. **9**(12): p. 961-6.
46. Pelner, L., G.A. Fowler, and H.C. Nauts, *EFFECT OF CONCURRENT INFECTIONS AND THEIR TOXINS ON THE COURSE OF LEUKEMIA*. Acta Medica Scandinavica, 1958. **162**(S338): p. 5-24.
47. Kelly, E. and S.J. Russell, *History of oncolytic viruses: genesis to genetic engineering*. Mol Ther, 2007. **15**(4): p. 651-9.
48. Wong, Y.L., et al., *The small molecule ISRIB rescues the stability and activity of Vanishing White Matter Disease eIF2B mutant complexes*. Elife, 2018. **7**.
49. Zheng, S.Q., et al., *MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy*. Nat Methods, 2017. **14**(4): p. 331-332.
50. Zhang, K., *Gctf: Real-time CTF determination and correction*. J Struct Biol, 2016. **193**(1): p. 1-12.
51. Scheres, S.H., *RELION: implementation of a Bayesian approach to cryo-EM structure determination*. J Struct Biol, 2012. **180**(3): p. 519-30.
52. Punjani, A., et al., *cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination*. Nat Methods, 2017. **14**(3): p. 290-296.
53. Xu, J., M. McPartlon, and J. Li, *Improved protein structure prediction by deep learning irrespective of co-evolution information*. Nature Machine Intelligence, 2021.
54. Pettersen, E.F., et al., *UCSF Chimera--a visualization system for exploratory research and analysis*. J Comput Chem, 2004. **25**(13): p. 1605-12.

- 897 55. Adams, P.D., et al., *PHENIX: a comprehensive Python-based system for*
898 *macromolecular structure solution*. Acta Crystallogr D Biol Crystallogr, 2010.
899 **66**(Pt 2): p. 213-21.
- 900 56. Emsley, P. and K. Cowtan, *Coot: model-building tools for molecular graphics*.
901 Acta Crystallogr D Biol Crystallogr, 2004. **60**(Pt 12 Pt 1): p. 2126-32.
- 902 57. Chen, V.B., et al., *MolProbity: all-atom structure validation for macromolecular*
903 *crystallography*. Acta Crystallogr D Biol Crystallogr, 2010. **66**(Pt 1): p. 12-21.
904